憑藉大約 100 個臨床和臨床前進行中項目，以及 2025 年提供 15 個以上新藥批准的潛力，我們繼續保持以創新為長期發展的主導。
With a pipeline of around 100 clinical and pre-clinical projects, and the potential to deliver up to 15 new medicine approvals by 2025, we continue our track record of long-term innovation-led performance.
